Vor Biopharma Inc (VOR)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $1.19B
Last updated: Nov 17, 2026 at 11:05 AM ET
Vor Biopharma Inc (VOR) Stock Forecast
Analysts expect Vor Biopharma (VOR) to earn -$6.67 per share in the fiscal year ending Dec 31, 2026. Of 10 analysts, 9 rate the stock Buy or Strong Buy, 1 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 0 estimates for the fiscal year ending Dec 31, 2026 were revised up and 1 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 10 ratings average 2.00, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 90% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 1 | 10.0% |
| Buy | 8 | 80.0% |
| Hold | 1 | 10.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 10
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss.
- Fiscal year ending Dec 31, 2026
- -$6.67
- EPS consensus
- Fiscal year ending Dec 31, 2027
- -$3.34
- EPS consensus
- Next report
- Mar 29, 2027
- Estimated
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$6.67 | -$8.64 to -$3.40 | 4 |
| Dec 31, 2027 | -$3.34 | -$3.90 to -$2.53 | 4 |
Quarterly Estimates
The EPS consensus falls from -$0.95 for the quarter ending Dec 31, 2026 to -$0.99 for the quarter ending Mar 31, 2027.
EPS range
| Quarter ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$0.95 | -$1.17 to -$0.78 | 11 |
| Mar 31, 2027 | -$0.99 | -$0.99 to -$0.99 | 1 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 2 upward and 1 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 0 | 1 |
| Fiscal year ending Dec 31, 2027 | 2 | 0 |
| Quarter ending Mar 31, 2027 | 0 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$6.90.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$6.67 | -$6.89 | -$6.53 | -$6.53 | -$6.90 | N/A |
| Fiscal year ending Dec 31, 2027 | -$3.34 | -$3.67 | -$3.82 | -$3.81 | -$3.74 | N/A |
Frequently Asked Questions About VOR
What is the VOR stock forecast?
Consensus analyst estimates put Vor Biopharma's EPS at -$6.67 for the fiscal year ending Dec 31, 2026. The consensus rating from 10 analysts is Buy.
How do analysts rate VOR stock?
Of 10 analysts covering Vor Biopharma, 1 rates it Strong Buy, 8 Buy, 1 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from VOR next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$6.67, with estimates from -$8.64 to -$3.40 from 4 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$3.34, with estimates from -$3.90 to -$2.53 from 4 analysts.
How many analysts cover VOR?
10 analysts rate Vor Biopharma stock, and 4 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
VOR pages: Overview, Earnings, Forecast, Financials, Competitors